title: The other path for follow-ons.
abstract: With follow-on biologics essentially dead in the water in the US, the decision of the world's largest generics manufacturer to invest in a platform for enhancing protein pharmacokinetics could pay dividends.
mesh_terms: D001702:Biopharmaceutics / Q000639:trends*; D004345:Drug Industry / Q000639:trends*; D016568:Drugs, Generic; D038622:Internationality; D013810:Therapeutic Equivalency; D014481:United States
chemical_list: D016568:Drugs, Generic